FRIDAY, March 23 (HealthDay News) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting stents, according to a meta-analysis published online March 23 in The Lancet.
Tullio Palmerini, M.D., from the Policlinico S. Orsola in Bologna, Italy, and colleagues compared the risk of thrombosis between bare-metal and drug-eluting stents in an analysis of 49 trials involving 50,844 patients.
The researchers found that, compared with bare-metal stents, the one-year definite stent thrombosis rate was significantly lower with CoCr-EES (odds ratio [OR], 0.23). This difference was seen as early as 30 days (OR, 0.21) and continued to be significant from 31 days to one year (OR, 0.27). Compared with paclitaxel-eluting stents, permanent polymer-based sirolimus-eluting stents, phosphorylcholine-based zotarolimus-eluting stents, and Resolute zotarolimus-eluting stents, CoCr-EES were associated with significantly lower rates of one-year definite stenosis (ORs, 0.28, 0.41, 0.21, and 0.14, respectively). CoCr-EES correlated with significantly lower rates of definite stent thrombosis compared with bare-metal and paclitaxel-eluting stents after two years of follow-up (OR, 0.35 and 0.34, respectively). At two-year follow-up, no other drug-eluting stent had lower definite thrombosis rates compared with bare-metal stents.
"In randomized studies completed to date, CoCr-EES has the lowest rate of stent thrombosis within two years of implantation. The finding that CoCr-EES also reduced stent thrombosis compared with bare-metal stents, if confirmed in future randomized trials, represents a paradigm shift," the authors write.
Several authors disclosed financial ties to the pharmaceutical, medical device, and biotechnology industries.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
